RecruitingNCT06755671

A Prospective Multicentre Real-world Assessment of the Efficacy of Danning Tablets in Alleviating Digestive Symptoms


Sponsor

Shanghai Hutchison Pharmaceuticals Limited

Enrollment

4,500 participants

Start Date

Apr 30, 2025

Study Type

OBSERVATIONAL

Conditions

Summary

The goal of this observational study is to evaluate if Danning Tablets are effective in alleviating dyspepsia in patients with any of the following digestive symptoms: upper abdominal pain, bloating, loss of appetite, acid reflux or constipation. The main questions it aims to answer are: How effective are Danning Tablets for patients with indigestion symptoms? What are the impact factors (e.g. severity of conditions, demographic features, dose and length of treatment etc.) of the efficacy of Danning Tablets for indigestion patients? Participants already taking Danning Tablets as part of their regular medical care for indigestion will take questionnaires by the end of two weeks and four weeks respectively from the start of their treatment.


Eligibility

Min Age: 18 YearsMax Age: 75 Years

Inclusion Criteria4

  • Patients between 18 and 75 years old
  • Patients with at least one of the following symptoms: upper abdominal pain, bloating, loss of appetite, acid reflux or constipation
  • Patients already taking Danning Tablets as part of their regular medicine treatment for dyspepsia
  • Patients agree to sign the informed consent form

Exclusion Criteria7

  • Past history or comorbidity of malignant tumor
  • Comorbidity of severe systemic condition including cardiovascular, cerebrovascular, renal and hematopoietic system diseases
  • Past history of abdominal surgery (post pancreatic surgery, post subtotal gastrectomy; incomplete intestinal obstruction) or mental illness, mobility difficulty (e.g. long-term bed ridden)
  • Comorbidity of any unstable chronic or acute disease,which may impact the evaluation of treatment efficacy as determined by the research physician
  • Pregnancy or breastfeeding
  • Participation in other clinical trials within the past 3 months
  • Other circumstances determined as ineligible by the research physician

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGDanning Tablet

Danning Tablet is the only exposure in this observational study.


Locations(1)

The Second Affiliated Hospital Zhejiang University School of Medicine

Hangzhou, Zhejiang, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06755671


Related Trials